NCT07352774

Brief Summary

This study aimed to evaluate the effects of laughter therapy on respiratory functions and geriatric pain in elderly individuals.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 6, 2025

Completed
10 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 16, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 24, 2025

Completed
22 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 20, 2026

Completed
Last Updated

January 20, 2026

Status Verified

January 1, 2026

Enrollment Period

10 days

First QC Date

December 24, 2025

Last Update Submit

January 13, 2026

Conditions

Keywords

Laughter TherapyRespiratory FunctionPainElderly

Outcome Measures

Primary Outcomes (6)

  • Geriatric Pain Scale

    The original scale, called the Geriatric Pain Measure, is a twenty-four-item multidimensional scale developed by Ferrell and colleagues in 2000. The scale adapted for Turkish has five dimensions, as in the original. It includes subscales for pain withdrawal (items 19, 20, 22, and 23), pain intensity (items 1, 2, 3, 4, 5, and 6), pain with movement (items 9, 10, 11, and 12), pain due to strenuous activities (items 7, 8, 18, 21, and 24), and pain due to other activities (items 13, 14, 15, 16, and 17). The scale includes two open-ended questions (items 19 and 20). These questions are scored from 0 to 10. For the other 22 items, each "Yes" response is summed and multiplied by 2.38. The total possible score ranges from 0 to 100. A score between 0 and 29 indicates mild pain, a score between 30 and 69 indicates moderate pain, and a score of 70 or above indicates severe pain. The total Cronbach's alpha value for the scale is 0.85.

    4 weeks

  • Forced Vital Capasity: FVC

    Mean Change from Baseline in Forced Vital Capacity (FVC) at Week 4. FVC is the total amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. It will be used to assess the improvement or stabilization of total lung volume. Unit of Measure: Liters (L)

    4 weeks

  • Forced Expiratory Volume in 1 Second: FEV1

    Mean Change from Baseline in Forced Expiratory Volume in 1 Second at week 4. The absolute volume of air exhaled during the first second of the forced vital capacity maneuver. The highest value from three acceptable maneuvers will be recorded in liters (L).

    4 weeks

  • FEV1/FVC Ratio

    Mean Change from Baseline in FEV1/FVC Ratio at Week 4. This ratio (Tiffeneau-Pinelli index) represents the percentage of vital capacity a person can deliver in the first second of a forced exhalation. It is used to differentiate obstructive and restrictive lung patterns. Unit of Measurement: Percentile

    4 weeks

  • Peak Expiratory Flow: PEF

    Mean Change from Baseline in Peak Expiratory Flow (PEF) at Week 4. PEF measures the maximum exhalation rate. Unit of Measurement: Liters/minute (L/min)

    4 weeks

  • Forced Expiratory Flow: FEF 25-75

    Change from Baseline in Forced Expiratory Flow Between 25% and 75% of Vital Capacity (FEF 25-75%) at Week 4. This measure reflects the flow rate during the middle half of the FVC maneuver and is a sensitive indicator of small airway function. Unit of Measure: Liters per second (L/sec)

    4 weeks

Secondary Outcomes (1)

  • Oxygen Saturation

    4 weeks

Study Arms (2)

Control Group

NO INTERVENTION

A pulmonary function test and a geriatric pain scale were administered to this group. No intervention was made. A pulmonary function test and a geriatric pain scale were administered again one month later.

Laughter Therapy

EXPERIMENTAL

A pulmonary function test and a geriatric pain scale were administered to this group and this group received laughter therapy 8 times in total, twice a week for 1 month. Respiratory function test and geriatric pain scale were applied before the intervention.

Behavioral: Laughter Therapy

Interventions

A laughter therapy session lasts 45-50 minutes. It includes 10 minutes of warm-up exercises, 15 minutes of breathing exercises, and 15 minutes of laughter exercises. It concludes with a 5-10-minute meditation.

Laughter Therapy

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Members of the Dikmen Retirees' Club, who do not accept to leave, are 60 years of age or older, have any work, visual, mental or orthopedic disability that would prevent them from participating in the sections, including those who smoke and use alcohol.

You may not qualify if:

  • Being under 60 years of age and having conditions that prevent the application of laughter therapy (having had abdominal surgery in the last three months, glaucoma, hernia and epilepsy), smoking and drinking alcohol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara University

Ankara, Ankara, 06230, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Respiratory AspirationPain

Interventions

Laughter Therapy

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Mind-Body TherapiesComplementary TherapiesTherapeutics

Study Officials

  • Fatma Özlem Öztürk, ASSOCİATE PROFESSOR

    ANKARA UNİVERSİTY

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Two randomly controlled groups.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 24, 2025

First Posted

January 20, 2026

Study Start

November 6, 2025

Primary Completion

November 16, 2025

Study Completion

January 15, 2026

Last Updated

January 20, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

De-identified individual participant data will be made available upon request.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Data will be available beginning 6 months after publication of the study results and for a period of 5 years.
Access Criteria
Researchers must provide a formal request and a statistically sound proposal to access the data. Requests will be reviewed by the principal investigator.

Locations